Fig. 6From: Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysisForest plots. The pooled proportion of the reported grades 3 or 4 adverse event rates in patients who received FOLFOXIRI + anti-EGFR antibody (A diarrhea. B neutropenia)Back to article page